AU2024901504A0 - Enhanced chimeric antigen receptor t cell composition and method of use - Google Patents

Enhanced chimeric antigen receptor t cell composition and method of use

Info

Publication number
AU2024901504A0
AU2024901504A0 AU2024901504A AU2024901504A AU2024901504A0 AU 2024901504 A0 AU2024901504 A0 AU 2024901504A0 AU 2024901504 A AU2024901504 A AU 2024901504A AU 2024901504 A AU2024901504 A AU 2024901504A AU 2024901504 A0 AU2024901504 A0 AU 2024901504A0
Authority
AU
Australia
Prior art keywords
antigen receptor
chimeric antigen
cell composition
enhanced chimeric
enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024901504A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Filing date
Publication date
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of AU2024901504A0 publication Critical patent/AU2024901504A0/en
Priority to PCT/AU2025/050536 priority Critical patent/WO2025241005A1/en
Pending legal-status Critical Current

Links

AU2024901504A 2024-05-22 2024-05-22 Enhanced chimeric antigen receptor t cell composition and method of use Pending AU2024901504A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2025/050536 WO2025241005A1 (en) 2024-05-22 2025-05-22 Enhanced chimeric antigen receptor t cell composition and method of use

Publications (1)

Publication Number Publication Date
AU2024901504A0 true AU2024901504A0 (en) 2024-06-06

Family

ID=

Similar Documents

Publication Publication Date Title
WO2024081544A3 (en) Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.2
IL295381B1 (en) Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
AU2024221322A1 (en) Antibodies that bind interleukin 4 receptor alpha and methods of use
CA3263303A1 (en) Methods of manufacturing chimeric antigen receptor t cells
IL316918A (en) Chimeric antigen receptor and il-18 receptor compositions and methods of use therein
CA3261520A1 (en) Antibodies and methods of making and using same
CA3245328A1 (en) Anti-folate receptor alpha antibodies and methods of use
IL319935A (en) Compositions and methods for enhancing adoptive t cell therapeutics
CA3266931A1 (en) Anti-napi2b antibodies and methods of use
CA3261512A1 (en) Anti-gpnmb antibodies and methods of use thereof
CA3267760A1 (en) Chimeric antigen receptor and cell including chimeric antigen receptor
EP4247856A4 (en) Chimeric antigen receptor t cell and method
HK40099106A (en) Chimeric antigen receptor t cell and method
AU2020904256A0 (en) Chimeric Antigen Receptor T Cell and Method
HK40101843A (en) Antigen specific t cells and methods of making and using same
AU2024901053A0 (en) Modified CD19-targeted chimeric antigen receptor (CAR)-T cell and uses thereof
CA3272279A1 (en) Blockade of cd3 expression and chimeric antigen receptors for immunotherapy
AU2024900713A0 (en) Antibodies and methods of use thereof
HK40131910A (en) Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
CA3272413A1 (en) Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
HK40126531A (en) Antibodies and methods of making and using same
CA3270441A1 (en) Compositions and methods of using cell-penetrating antibodies
AU2024379216A1 (en) Anti-dll3 antibody and method of making and using thereof
AU2024903429A0 (en) Lambda myeloma antigen chimeric antigen receptors and uses thereof
IL320555A (en) Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same